Chronic itch is an unpleasant sensation and reduces quality of life. Especially, atopic dermatitis (AD) is representative disease with chronic itch. The itching associated with a nettle rash is potently alleviated by H₁ receptor antagonists, but that with AD is not. Nevertheless, its underlying mechanisms are poorly understood. Here, using AD model mice, we showed inhibitory effect of the novel gabapentinoid, mirogabalin on spontaneous scratching behavior. The number of scratch bouts were increased in AD model mice as compared with healthy mice. These spontaneous scratching were not suppressed by H₁ receptor antagonist. Next, we examined the effect of mirogabalin (10 mg/kg) by oral administration in AD model mice, and mirogabalin suppressed scratch bouts. We also examined sedation by using healthy mice with Rota-Rod test and showed mirogabalin (10 mg/kg) did not have sedation. Furthermore, we examined the effect of other gabapentinoids. Gabapentin (100 mg/kg) and pregabalin (30 mg/kg) also inhibited scratch bouts in AD model mice.  These results suggest that mirogabalin may be effective against chronic pruritus in AD.